Jonathon Posthumus, MD
Allergy & Immunology · Fredericksburg, VANPI 1255536553
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 457 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations.
Across 457 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$859
- Sanofi$619
- Pfizer$420
- Kaleo, Inc.$377
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,61799%
- Education$811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 97 | $1,882 |
| GSK | 93 | $1,565 |
| Regeneron Healthcare Solutions, Inc. | 42 | $859 |
| Sanofi | 29 | $619 |
| Pfizer | 24 | $420 |
| Kaleo, Inc. | 21 | $377 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $366 |
| Novartis | 18 | $331 |
| Genentech USA, Inc. | 21 | $273 |
| Optinose US, Inc. | 15 | $264 |
| Grifols USA, LLC | 7 | $219 |
| Amgen | 12 | $206 |
| CSL Behring | 8 | $186 |
| Pharming Healthcare, Inc. | 10 | $176 |
| Incyte Corporation | 5 | $113 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $110 |
| LEO Pharma Inc. | 4 | $93 |
| Biocryst US Sales Co., LLC | 2 | $86 |
| Covis Pharma GmbH | 3 | $61 |
| Azurity Pharmaceuticals, Inc. | 3 | $61 |
| Boehringer Ingelheim | 4 | $58 |
| Shire North American Group Inc | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Ionis Pharmaceuticals, Inc. | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Biocryst Pharmaceuticals, Inc. | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $20 |
| Merck | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Blueprint Medicines Corporation | 1 | $18 |
| Alk-abello, Inc | 1 | $18 |
| Circassia Inc. | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$100
How this compares
$8,698 in reported general payments places this provider in the 70th percentile of 133 allergy & immunology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 11 | $131,825 |
| XolairOmalizumab | 12 | $32,703 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $22,935 |
| Advair HfaFluticasone Propion/Salmeterol | 41 | $20,758 |
| Arnuity ElliptaFluticasone Furoate | 42 | $12,070 |
| DuleraMometasone/Formoterol | 28 | $10,387 |
| Epinephrine | 54 | $9,720 |
| Spiriva RespimatTiotropium Bromide | 18 | $9,076 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $6,282 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $3,381 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $3,138 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 91 | $2,608 |
| Azelastine Hcl | 80 | $2,000 |
| Olopatadine Hcl | 15 | $1,495 |
| Montelukast Sodium | 111 | $1,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Arnuity Ellipta | $1,565 | $166,83085 claims |
| MerckDulera | $20 | $10,38728 claims |
| Boehringer IngelheimSpiriva Respimat | $58 | $9,07618 claims |
| AstraZenecaSymbicort | $1,882 | $6,28224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 133 allergy & immunology providers in Virginia.
Other allergy & immunology in Fredericksburg
- Andrew KimFredericksburg$104K
- Ahmed ButtFredericksburg$59K
- Jonathan MozenaFredericksburg$14K
- Julie AbrahamFredericksburg$11K
- Charles LaneLynchburg$1.4M
- Jacqueline Eghrari-SabetVienna$1M
- Eric KarlinWilliamsburg$522K
- Nicholas RiderRoanoke$227K
- Courtney BlairMc Lean$139K
- Behnam DaghighLeesburg$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.